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Abstract The aim of this study was to determine the mechan-
isms of curcumin-induced human breast cancer cell apoptosis.
From quantitative image analysis data showing an increase in the
percentage of cells with a sub-G0/G1 DNA content, we
demonstrated curcumin-induced apoptosis in the breast cancer
cell line MCF-7, in which expression of wild-type p53 could be
induced. Apoptosis was accompanied by an increase in p53 level
as well as its DNA-binding activity followed by Bax expression
at the protein level. Further experiments using p53-null
MDAH041 cell as well as low and high p53-expressing TR9-7
cell, in which p53 expression is under tight control of
tetracycline, established that curcumin induced apoptosis in
tumor cells via a p53-dependent pathway in which Bax is the
downstream effector of p53. This property of curcumin suggests
that this molecule could have a possible therapeutic potential in
breast cancer patients. ß 2002 Published by Elsevier Science
B.V. on behalf of the Federation of European Biochemical So-
cieties.
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1. Introduction
Curcumin (diferuloylmethane), a naturally occurring phyto-
chemical responsible for the yellow color of the commonly
used spice turmeric (Curcuma longa Linn), is receiving atten-
tion from cancer investigators because of its chemopreventive
properties against human malignancies. The anti-carcinogenic
properties of curcumin in animals have been demonstrated by
its inhibition of tumor initiation induced both by various car-
cinogens and by phorbol esters [1^3]. Recent reports also
demonstrated the anti-tumor property of curcumin in cancers
of colon, forestomach, breast etc. [2^5]. Besides its anti-carci-
nogenic e¡ects, curcumin has been reported to have a wide
range of pharmacological properties including anti-in£amma-
tory, anti-toxic and anti-oxidative [6^8]. The pharmacological
safety of curcumin is demonstrated by its consumption for
centuries at up to 100 mg/day by people in certain countries
[9]. It has been found to reduce the number of cells with
chromosomal aberrations but protects normal cells from chro-
matid breaks due to exposure to Q-radiation [10]. However,
the mechanisms underlying these diverse e¡ects of curcumin
are not fully understood. Among the possibilities, regulation
of an array of cellular biochemical processes such as inhibi-
tion of nitric oxide synthase, receptor tyrosine kinase and
protein kinase C [3,11,12] activities and the alteration of tran-
scriptional factors c-jun/AP-1 and nuclear factor UB, p53 by
curcumin have been suggested [13,14]. Recently it has also
been suggested that production of reactive oxygen intermedi-
ates may be the cause of tumor cell apoptosis as a result of
curcumin treatment [15].
Mechanisms that suppress tumorigenesis often involve
modulation of signal transduction pathways, leading to alter-
ations in gene expression, arrest of cell cycle progression or
apoptosis. Apoptosis is a mode of cell death used by multi-
cellular organisms to eradicate cells in diverse physiological
and pathological settings. Several studies have demonstrated
that apoptosis may be involved in cell death induced by che-
motherapeutic agents, including cisplatin, camptothecin, eto-
poside etc. There is accumulating evidence that the e⁄ciency
of anti-tumor agents is related to the intrinsic propensity of
the target tumor cells to respond to these agents by apoptosis
[16]. Recent evidence also shows that suppression of apoptosis
by tumor-promoting agents in pre-neoplastic cells is thought
to be an important mechanism in tumor promotion [17]. In
this context, it is noteworthy that apoptosis-inducing ability
seems to have become a primary factor in considering the
e⁄ciency of chemopreventive agents.
The tumor suppressor gene p53 is important in the etiology
of cancer and is mutated, deleted, or rearranged in more than
half of all human tumors [18]. p53 mediates either apoptosis
or cell cycle arrest in response to DNA damage, thus acting as
a molecular ‘guardian of the genome’ [19^21], each of which
operates in a distinct context. This tumor suppressor protein
not only controls the transition of cells from the G1 to S
phase or G2 to M, but it is also capable of inducing pro-
grammed cell death [22]. In contrast, in normal cells, p53-
mediated growth arrest prevents the replication of damaged
DNA, reduces genetic instability and allows the cells to per-
form critical repair functions before progressing through the
cell cycle [22^24], whereas apoptosis induced by p53 is neces-
sary for eliminating aberrant cells. Bax, the pro-apoptotic
member of the Bcl-2 family, has also been shown to be a
p53 target and is up-regulated in a number of systems during
p53-mediated apoptosis. On the other hand, the up-regulation
of Bax expression and down-regulation of Bcl-2 have been
demonstrated during apoptosis [19,25]. Recent observations
not only implicated p53 signaling pathway in the transcrip-
tional activation of Bax in apoptosis, but also in the alteration
of the Bcl-xL (pro-proliferative member of the Bcl-2 family)/
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Bax ratio [26], thereby indicating that cross-talk between these
pro- and anti-apoptotic proteins is one of the important fac-
tors deciding the fate of a cell. However, the role of curcumin
in regulating the balance between these pro- and anti-apopto-
tic factors is not yet revealed.
In the present study, we addressed the relevance of p53 and
its downstream e¡ectors, Bax and Bcl-xL, in curcumin-in-
duced human breast cancer (MCF-7) cell apoptosis. We sug-
gest that such a multi-marker analysis of apoptosis pathways
could be useful for individualization of therapeutic strategies
in the future.
2. Materials and methods
2.1. Materials
Fetal bovine serum (FBS), Dulbecco’s modi¢ed Eagle’s medium
(DMEM), streptomycin, penicillin, tetracycline, insulin, L-glutamine,
sodium pyruvate and non-essential amino acids were purchased from
Gibco BRL (Gaithersburg, MD, USA). Curcumin, 4P,6P-diamidino-2-
phenylindole (DAPI), T4 polynucleotide kinase and general reagents
were purchased from Sigma (St. Louis, MO, USA). Polyclonal anti-
Bcl-xL and anti-Bax, anti-K-actin antibodies, horseradish peroxidase-
conjugated goat anti-mouse and goat anti-rabbit antibodies were ob-
tained from Pharmingen (San Diego, CA, USA). Wild-type anti-p53
antibody (monoclonal) was obtained from Oncogene Science (Cam-
bridge, MA, USA). The consensus p53 binding palindromic oligonu-
cleotide (5P-GGACATGCCCGGGCATGTCC-3P) was synthesized by
Operon Technologies (Alameda, CA, USA). [K-32P]dATP (speci¢c
activity 3000 Ci/mmol) was purchased from BRIT (India). The re-
maining chemicals were purchased from local ¢rms (India) and were
of highest purity grade.
2.2. Cell culture
Human breast cancer cells (MCF-7) were obtained from NCCS,
India. The MDAH041 post-crisis cell line was derived from the ¢bro-
blasts of a patient with Li^Fraumeni syndrome. There is a frameshift
mutation of one p53 allele at codon 184 and the normal p53 allele has
been lost during in vivo propagation [27]. TR9-7 cells, expressing
wild-type p53 under the control of a tetracycline-regulated promoter,
were derived from MDAH041 cells [28]. Cells were routinely main-
tained in DMEM supplemented with 10% fetal bovine serum, insulin
(0.1 U/ml), L-glutamine (2 mM), sodium pyruvate (100 Wg/ml), non-
essential amino acids (100 WM), antibiotics (100 Wg/ml streptomycin
and 50 U/ml penicillin) þ tetracycline (1 Wg/ml) at 37‡C in a humidi¢ed
incubator containing 5% CO2. Cells were trypsinized and sub-cultured
at 1:3 ratio for routine maintenance and experiments.
2.3. Quantitative image analysis of cell cycle phase distribution
MCF-7, MDAH41 or TR9-7 cells were grown as monolayers on
coverslips. After curcumin treatment the cells were ¢xed with chilled
methanol and stained with DAPI (0.2 Wg/ml for 20 min at room
temperature). The cells on coverslips were mounted with Vectashield
mounting medium (Vector Laboratories, Burlingame, CA, USA). A
Leica model DM 900 £uorescent microscope was used to visualize the
£uorescent images. The ¢lter cube A was used to detect the signal
from DAPI. Digital images were captured with a highly sensitive cool
(325‡C) CCD camera (Princeton Instruments) controlled with Meta-
morph software (Universal Imaging) [29]. The exposure times were
adjusted so that the brightest signal in the specimen gave less than
90% of the maximum linear range for the camera (a gray scale of 0^
4096; 16 bit Images). Each captured image was corrected by subtract-
ing the background image followed by shading correction (to correct
the uneven signal collection across the ¢eld). The nuclear region of
each cell was de¢ned by image analysis of DAPI pictures. Then the
£uorescence signal from individual nuclear regions was integrated us-
ing Metamorph image analysis features. The relative £uorescence data
were transferred to Microsoft Excel and processed.
2.4. Western blotting
For Western blot analysis of p53, Bcl-xL and Bax an aliquot of 50
Wg protein from the lysates of MCF-7 cells (untreated or curcumin-
treated) was mixed with an equal volume of 2USDS^PAGE sample
bu¡er, heated at 100‡C for 5 min and loaded onto a 10% SDS poly-
acrylamide gel. After electrophoresis the gel was transferred to a ni-
trocellulose membrane on a semidry transfer apparatus from Bio-Rad.
The membrane was blocked with 3% non-fat milk in phosphate-bu¡-
ered saline containing 0.05% Tween 20 prior to antibody treatments.
The protein of interest was visualized by enhanced chemilumines-
cence. The blot was then stripped in bu¡er (62.5 mM Tris^HCl pH
6.8, 2% SDS, 200 mM 2-mercaptoethanol) at 50‡C for 30 min. After
extensive washing, the blot was used again for probing the next mol-
ecule, beginning from the blocking.
2.5. Gel electrophoresis mobility shift assay
Gel electrophoresis mobility shift assay was done as described [30].
Double-stranded p53 protein-binding consensus oligonucleotide was
end-labeled by T4 polynucleotide kinase. Protein^DNA complexes
were separated by electrophoresis on 4% polyacrylamide gel electro-
phoresis. The supershift was induced with 0.2 Wg/assay of anti-p53
antibody. Twenty-fold unlabeled oligonucleotide competitor was
added at the same time as the radiolabeled probe was added to the
reaction mixture. The gel was dried and exposed to a PhosphorImager
screen for 90 min and quantitation was done using the Molecular
Analysis program (Bio-Rad).
3. Results
3.1. E¡ect of curcumin on MCF-7 cell cycle progression
We employed quantitative image analysis techniques to ap-
praise the e¡ect of curcumin on the MCF-7 cell cycle phase
distribution. Twenty-four hours of continuous exposure to
di¡erent doses of curcumin resulted in cessation of cell growth
followed by signi¢cant cell death. Optimum inhibition was
obtained at a dose of 25 WM, beyond which no further de-
crease in cell number could be obtained. The LD50 of curcu-
min was 10 WM for MCF-7 cells (data not shown). It was
observed that at 10 WM curcumin, the percentage of cells in
G0/G1 phases decreased with a concomitant increase of cell in
the sub-G0/G1 phase up to 24 h. After 24 h the percent of
sub-G0/G1 phase cells decreases (Fig. 1). Phenotypically, ap-
optosis is characterized by cell shrinkage, chromatin compac-
tion, nuclear blebbing and collapse of the nucleus into small
intact fragments (apoptotic bodies) which were evident from
the DAPI-stained £uorescent images of curcumin-treated
MCF-7 nucleus (not shown).
3.2. E¡ect of curcumin on the expression of p53, Bcl-xL
and Bax
p53 has been found to be importantly involved in apoptosis
induced by a broad range of agents. We examined by Western
blot analysis, using antibody directed against wild-type p53,
whether curcumin has any e¡ect on the expression of this pro-
apoptotic protein in MCF-7 cells. Results in Fig. 2 shows that
upon 10 WM curcumin treatment, p53 started increasing from
as early as 4 h, reached a maximum level by 12 h and per-
sisted up to 24 h. At 48 h of curcumin treatment the level of
p53 was found to decrease to control level. The level of Bcl-xL
was moderately high in MCF-7 cells and remained almost
unaltered after curcumin treatment (Fig. 2A,B). On the other
hand, the level of Bax increased signi¢cantly after 8 h and
attained a peak at 24 h after curcumin treatment (Fig.
2A,B). The p53, Bcl-xL and Bax levels were measured by
quantitative Western blot analysis after normalizing with
K-actin content. Interestingly, it is to be noted that the ex-
pression of p53 precedes Bax expression in MCF-7 cells as a
result of curcumin treatment. Since it is known that p53 can
transactivate Bax expression [31], our observation leads to the
possibility that curcumin induces MCF-7 cell apoptosis in a
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p53-dependent pathway in which Bax is a downstream e¡ec-
tor molecule.
3.3. Role of curcumin in p53 DNA-binding activity in
MCF-7 cells
Next, using a gel electrophoresis mobility shift assay, we
examined the relative activity of p53 to bind its known cog-
nate sequence. In nuclear extracts of curcumin-treated MCF-7
cells, a band corresponding to the p53^DNA complex was
detected (Fig. 2C). The band intensity began to increase at
4 h, reached a maximum level by 24 h and then declined at 48
h after curcumin treatment. The speci¢city of this binding was
con¢rmed by competition analysis with a 20-fold excess of
unlabeled homologous oligonucleotide. The presence of p53
in the complex with retarded mobility in the gel was identi¢ed
by further retardation of the band following incubation with
p53 antibody (Fig. 2C). All these data indicate that MCF-7
cells express wild-type p53 protein and the DNA-binding ac-
tivity of the same is induced by curcumin.
3.4. Involvement of p53 in curcumin-induced Bax expression
Since p53 expression was found to precede Bax expression,
we hypothesized that curcumin induced Bax expression
through the transactivation by p53. To test this hypothesis,
we used p53-null (MDAH041) as well as tetracycline-regu-
lated wild-type p53 expressing cell lines (TR9-7) originating
from a post-crisis cell line derived from the ¢broblasts of a
patient with Li^Fraumeni syndrome [28]. No immunoreactiv-
ity of p53 could be found in p53-null MDAH041 cells even
when the cell were treated with 10 WM curcumin for 24 h (Fig.
3A). In these cells the content of Bcl-xL remained unaltered in
the case of curcumin treatment. Interestingly, curcumin treat-
ment failed to show the appearance of Bax in this p53-null cell
line (Fig. 3A). On the other hand, in tetracycline-regulated
TR9-7 cells, expression of wild-type 53 was low and increased
moderately with simultaneous increase in Bax when cells were
treated with curcumin (Fig. 3A). However, the level of Bcl-xL
expression is slightly inhibited by curcumin under this condi-
tion (Fig. 3A). Under the tetracycline-withdrawn condition,
Fig. 1. Curcumin-induced cell cycle phase distribution of MCF-7 cells. Cell cycle phase distribution of MCF-7 nuclear DNA was determined
by quantitative-image analysis as described in Section 2. At di¡erent times after curcumin treatment, cells were ¢xed and stained with DAPI
and analyzed for DNA content by £uorescent microscopy. The normal DNA content was determined from ‘0 h’ cells where the predominant
peak corresponded to the normal G0/G1 content of DNA (2n). The DNA content in curcumin-treated cells was displayed in di¡erent panels in-
dicated by their corresponding time of incubation. Less than 2n DNA content was regarded as sub-G0/G1 peak or apoptotic cells.
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the expression of p53 was high and it was further elevated by
curcumin treatment. Bax expression in these high p53-express-
ing cells showed a dramatic increase in case of curcumin treat-
ment. In these cells the Bcl-xL level was low and remained
unaltered after curcumin treatment (Fig. 3A).
To determine the relative DNA-binding activity of p53,
nuclear extracts of curcumin-treated p53-null as well as low-
p53 (in the presence of tetracycline) and high-p53 (in the ab-
sence of tetracycline) cells were used and gel electrophoresis
mobility shift assay using the oligonucleotide of the p53-bind-
ing consensus sequence was employed. In nuclear extracts of
p53-null MDAH041 cells, no appreciable p53 DNA-binding
activity was observed. Even curcumin treatment could not
increase the intensity of this band (Fig. 3B). In tetracycline-
regulated low p53-expressing TR9-7 cells, a band correspond-
ing to the p53^DNA complex was detected (Fig. 3B). The
band intensity increased after curcumin treatment. In the
case of high p53-expressing TR9-7 cells, p53 DNA-binding
activity was already high and was further increased by curcu-
min pretreatment (Fig. 3B). All the above results suggest that
curcumin potentiates p53 DNA-binding which in turn induces
Bax expression.
3.5. Involvement of p53 in curcumin-induced apoptosis
To demonstrate that p53 is speci¢cally involved in curcu-
min-induced apoptosis, we used the p53-null cell line
(MDAH041) as well as tetracycline-regulated wild-type p53-
expressing cell line (TR9-7). In p53-null MDAH041 cells, cur-
cumin failed to induce apoptosis (Fig. 4). In TR9-7 cells,
curcumin moderately induced apoptosis in low p53-expressing
condition, i.e. in the presence of tetracycline, which down-
regulates wild-type p53 expression. In fact, under this condi-
tion, only 23% of cells underwent apoptosis (Fig. 4). On the
other hand, when TR9-7 cells were released from tetracycline-
inhibited p53 expression, curcumin induced a high level of
apoptosis. In this case, the number of cells containing hypo-
ploid or 6 2n DNA increased as a result of curcumin treat-
ment (s 50%). All these results signify that curcumin asserts
its apoptogenic e¡ect in a p53-dependent manner.
4. Discussion
The concept that cancer can be prevented or certain diet-
derived substances can postpone its onset is currently eliciting
considerable interest. Curcumin has been demonstrated to in-
hibit tumor initiation induced by various carcinogens. How-
ever, the molecular events of curcumin action have not been
studied in detail. The aim of this paper was thus to identify
the events which may ultimately initiate the apoptotic cascade
leading to cancer cell death as a result of curcumin treatment.
One of the most interesting questions in the p53 ¢eld is how
a cell makes the decision to undergo growth arrest or apopto-
sis. It has been proposed that p53 may induce two sets of
genes upon stress signals. One set mainly functions in cell
growth control, such as p21/Waf-1 and GADD45, and the
other set acts on apoptosis, such as Bax [23]. In this study,
Fig. 2. E¡ect of curcumin on the expression of p53, Bcl-xL and Bax proteins and induction of p53 DNA-binding activity. MCF-7 cells were
treated with 10 WM curcumin for di¡erent time intervals. A: Cell lysates were subjected to Western blot analysis for the determination of the
expression levels of p53, Bcl-xL and Bax using speci¢c antibodies. The blots were re-probed with anti-K-actin antibody to con¢rm equal protein
loading. B: The relative densities of each band were expressed graphically by quantitative Western blot analysis after normalizing with K-actin
band. C: Time-dependent induction of p53 DNA-binding activity in MCF-7 cells was determined by gel electrophoresis mobility shift assay.
To induce the supershift, the reaction mixture was incubated with anti-p53 antibody and a 20-fold excess of non-radioactive p53 probe was
used for the competition assay.
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we observed that curcumin is capable of inducing apoptosis in
breast carcinoma cell line MCF-7, in which expression of
wild-type p53 can be induced. The apoptosis is accompanied
by an increase in p53 level as well as its DNA-binding activity
followed by Bax expression at the protein level. Further ex-
periments using p53-null cells as well as TR9-7 cells, in which
wild-type p53 expression is under tight control of tetracycline,
established that curcumin induces apoptosis in tumor cells via
a p53-dependent pathway in which Bax is the downstream
e¡ector of p53.
It is well recognized that whether a cell becomes committed
to apoptosis partly depends upon the balance between pro-
teins that mediate cell death, e.g. Bax, and proteins that pro-
mote cell viability, e.g. Bcl-2 or Bcl-xL [25,26], and the ratio
of Bax to Bcl-2 or Bcl-xL appears to be a critical determinant
of a cell’s threshold for undergoing apoptosis [26]. Interest-
ingly, wild-type p53 has been shown to be capable of both
down-regulating the death suppressor Bcl-2 and up-regulating
the death promoter Bax, thereby changing the Bcl-2/Bax ratio
and disposing to programmed cell death [25,26]. Bax over-
expression has recently been shown to enhance radiation-in-
duced apoptosis, but only in the presence of functional p53
[31]. These observations clearly show that these oncoproteins
act in a well-regulated concerted manner to decide the ulti-
mate fate of any cell.
Keeping all this information in mind, we attempted to es-
tablish the relationship, if any, between p53 status, Bcl-2/Bax
ratio, cell cycle arrest and apoptosis in curcumin-treated tu-
mor cells. To achieve this goal we took three di¡erent ap-
proaches. In the ¢rst approach, we selected human breast
carcinoma cells (MCF-7) in which wild-type p53 is constitu-
tively expressed. In these cells, curcumin induced apoptosis
with an increase in p53 level. Interestingly, the curcumin-in-
duced increase in p53 expression precedes that of Bax thereby
leading us to hypothesize that p53 transactivates Bax expres-
sion. In these cells the Bcl-xL level remained almost un-
changed thereby shifting the Bcl-xL/Bax ratio towards apo-
ptosis. That activation of the p53 signaling pathway may play
a causative role in apoptosis by modulating the Bcl-xL/Bax
ratio has also been reported by Gonzalez de Aguilar et al.
[26]. All these observations point to the evidence for the im-
plication of p53 signaling pathway in curcumin-induced tumor
cell apoptosis and support the candidature of Bax as the
downstream e¡ector in this pathway.
To re-establish our ¢ndings, we took a second approach in
which the p53-null cell line (MDAH041; which has a frame-
shift mutation in one p53 allele and the normal allele has been
lost during in vivo propagation from ¢broblasts of a post-
crisis Li^Fraumeni patient [27,28]) was used as the experimen-
tal model. In these cells curcumin failed to induce either Bax
expression or apoptosis. These results support our hypothesis
that p53 is required for Bax expression as well as curcumin-
induced apoptosis. To further con¢rm these observations, we
took a third approach in which we used a well-controlled
system to regulate wild-type p53 expression with tetracycline
(TR9-7 cells ; MDAH041 cells over-expressed with tetracy-
cline-regulated wild-type p53). In the presence of the regulator
tetracycline curcumin increased the p53 level moderately with
a moderate elevation in Bax level. However, removal of tetra-
cycline and treatment of curcumin resulted in a dramatic in-
crease in p53 as well as Bax levels resulting in apoptosis. All
these data strongly con¢rm that p53 signaling acting via Bax
activation is essential for the apoptogenic e¡ect of curcumin.
These ¢ndings di¡er from those of Bush et al. [32] who
showed that curcumin-induced apoptosis in human melanoma
cells is independent of p53. In fact, melanoma cells rarely
contain mutant p53 and hardly undergo apoptosis by wild-
type p53 [33]. However, adenovirus-mediated transfer of p53
in these melanoma cells suppressed growth and induced apo-
ptosis [33]. Involvement of p53 in curcumin-induced apoptosis
of hepatoblastoma cells has also been documented [14]. All
these reports together with our ¢ndings suggest that depend-
ing on the nature and condition of the concerned cell, and the
circumstances involved, the downstream e¡ector of any sig-
naling agent that will come into play is determined. Thus, p53
signaling acting via Bax activation is essential for the apopto-
genic e¡ect of curcumin in our model system.
Over the years, cancer therapy had witnessed many exciting
developments, but cure of cancer has still remained as com-
plex as the disease itself, since the mechanisms of tumor kill-
ing are still not fully realized. Identi¢cation of individual com-
ponents of signaling pathways leading to tumor cell death as
well as targeted alteration of those molecules may be of im-
Fig. 3. Involvement of p53 in curcumin-induced Bax expression.
p53-null MDAH041 cells, low p53-expressing TR9-7 cells (in the
presence of tetracycline; +Tet) and high p53-expressing TR9-7 cells
(in the absence of tetracycline; 3Tet) were incubated with or with-
out 10 WM curcumin for 24 h. A: p53, Bcl-xL and Bax levels were
detected by enhanced chemiluminescence. B: Induction of p53
DNA-binding activity in p53-null MDAH041 cells, low p53-express-
ing (+Tet) and high p53-expressing (3Tet) TR9-7 cells was deter-
mined by gel electrophoresis mobility shift assay.
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mense help to selectively induce apoptosis in cancer cells.
Knowledge acquired from this study will, therefore, lead us
one step forward towards that goal.
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